Rubella serosurveys at three Aravind Eye Hospitals in Tamil Nadu, India.
OBJECTIVE
To determine the susceptibility of female eye hospital staff to rubella infection and the potential risk for hospital-based rubella outbreaks.


METHODS
A prospective cohort study on the seroprevalence of rubella IgG antibodies was conducted at three large eye hospitals in Coimbatore, Madurai and Tirunelveli, Tamil Nadu, India, where young children with eye abnormalities attributable to congenital rubella are treated. A total of 1000 female hospital employees aged 18-40 years agreed to participate and gave written informed consent.


RESULTS
The proportions of rubella-seronegative women were: 11.7% at Coimbatore, with a 95% confidence interval (CI) of 8.1-16.5; 15% at Madurai (95% CI = 12.3-18.1), and 20.8 at Tirunelveli (95% CI = 14.7-28.6). For the entire cohort the proportion seronegative was significantly higher among married women (21.5%) than among single women (14.0%) (P = 0.02). Rates of seronegativity were highest among physicians and lowest among housekeepers. All 150 seronegative women in the study sample accepted a dose of rubella vaccine.


CONCLUSIONS
These are the first rubella serosurveys to have been reported from eye hospitals in any country. The relatively high rate of susceptibility indicated a risk of a rubella outbreak, and this was reduced by vaccinating all seronegative women. A policy has been established at all three hospitals for the provision of rubella vaccine to new employees. Other hospitals, especially eye hospitals and hospitals in countries without routine rubella immunization, should consider the rubella susceptibility of staff and the risk of hospital-based rubella outbreaks.
Vijayalakshmi
Perumalsamy
P
Aravind Eye Hospital, Madurai, Tamil Nadu, India.
Anuradha
Rajamanickam
R
Prakash
Karthik
K
Narendran
Kalpana
K
Ravindran
Meenakshi
M
Prajna
Lalitha
L
Brown
David
D
Robertson
Susan E
SE
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D003428:Cross Infection / Q000517:prevention & control* / Q000821:virology; D004198:Disease Susceptibility / Q000821:virology; D005260:Female; D006782:Hospitals, Special; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007194:India / Q000453:epidemiology; D010564:Personnel, Hospital / Q000145:classification / Q000706:statistics & numerical data*; D011446:Prospective Studies; D012409:Rubella / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D012411:Rubella Vaccine / Q000008:administration & dosage; D012412:Rubella virus / Q000276:immunology*; D016036:Seroepidemiologic Studies; D014611:Vaccination
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D012411:Rubella Vaccine